CARB-X awards Specific Diagnostics $1.7 million

Create PDF

July 2018—CARB-X has awarded Specific Diagnostics up to $1.7 million to support the development of the company’s antibiotic susceptibility testing system. Up to $1.7 million more could be awarded based on achievement of project milestones. Specific’s AST instrument determines phenotypic antibiotic susceptibility within hours of blood infection.

“Specific Diagnostics’ project is an example of cutting-edge technology that could potentially speed up and change the way life-threatening infections are diagnosed and treated,” Kevin Outterson, executive director of CARB-X, said in a press release.